Checkpoint Therapeutics, Inc.

Back to All Transactions

Checkpoint Therapeutics, Inc.
For more information regarding this transaction contact:
  • Dave McDonald Investment Banking 612.326.1268

Lake Street is pleased to announce it served as the qualified independent underwriter for Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT), a clinical-stage immuno-oncology biopharmaceutical company, in its confidentially marketed public offering of 4,600,000 shares of its common stock at a public offering price of $4.35 per share.
 

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint’s lead product candidate is a fully-human monoclonal antibody licensed from the Dana-Farber Cancer Institute that targets programmed death-ligand 1 (“PD-L1”). Checkpoint commenced a Phase 1 clinical study for its anti-PD-L1 antibody, CK-301, in October 2017, evaluating the safety and tolerability of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, and plans to develop CK-301 as a treatment for patients with non-small cell lung cancer (“NSCLC”) and other solid tumors. In addition, Checkpoint is developing a small-molecule, targeted anti-cancer agent, CK-101, for the treatment of patients with epidermal growth factor receptor (“EGFR”) mutation-positive NSCLC. In September 2016, Checkpoint commenced the Phase 1 portion of a Phase 1/2 clinical study for CK-101. Checkpoint’s pipeline also includes antibodies that target glucocorticoid-induced TNFR-related protein (“GITR”) and carbonic anhydrase IX (“CAIX”), in addition to oral, small-molecule, targeted anti-cancer agents that inhibit bromodomain and extra-terminal (“BET”) proteins and poly (ADP-ribose) polymerase (“PARP”). Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

Contact

Mike Townley
Head of Investment Banking

612.326.1313

Email Mike
 

Dave McDonald
Head of Life Science Investment Banking

612.326.1268

Email Dave

 

Tim Klein

Investment Banking

612.260.6173

Email Tim

 

Rob Martin

Investment Banking

612.260.5850

Email Rob

 

Steve Rickman

Investment Banking

612.326.1985

Email Steve